Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System

• Published in: ClinicoEconomics and outcomes research Vol. 14; pp. 149 - 161
• Main Authors: Torres, Antoni, Soriano, Alex, Rivolo, Simone, Remak, Edit, Peral, Carmen, Kantecki, Michal, Ansari, Wajeeha, Charbonneau, Claudie, Hammond, Jennifer, Grau, Santiago, Wilcox, Mark
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2022; Dove; Dove Medical Press
• Subjects: Adults; Analysis; Antibiotics; Ceftaroline; ceftaroline fosamil; Cloxacillin; complicated skin and soft tissue infection; cost-consequences; Economic aspects; Health aspects; Health care industry; Hospital patients; Infection; Medical care, Cost of; Methicillin; Original Research; Pharmaceutical industry; Skin; spain; United States; Spain; ceftaroline fosamil; cost-consequences; complicated skin and soft tissue infection; Spain
• ISSN: 1178-6981; 1178-6981
• DOI: 10.2147/CEOR.S329494

Complicated skin and soft tissue infections (cSSTI) are associated with high healthcare resource use and costs. The emergency nature of cSSTI hospitalizations requires starting immediate empiric intravenous (IV) antibiotic treatment, making the appropriate choice of initial antibiotic therapy crucial. The use of ceftaroline fosamil (CFT) as an alternative to other IV antibiotic therapies for the empiric treatment of hospitalized adults with cSSTI (vancomycin, linezolid, daptomycin, cloxacillin, tedizolid) was evaluated through cost consequences analysis. The model structure was a decision tree accounting for four different pathways: patients demonstrating early response (ER) either discharged early (with oral antibiotic) or remaining in hospital to continue the initial therapy; non-responders either remaining on the initial IV therapy or switching to a second-line antibiotic. The model perspective was the Spanish National Health System. CFT resulted in average percentage of patients discharged early (PDE) of 24.6% (CI 19.49-30.2%) with average total cost per patient of €6763 (€6268-€7219). Vancomycin, linezolid, daptomycin and tedizolid resulted in average PDE of 22% (17.34-27.09%), 26.4% (20.5-32.32%), 28.6% (22.08-35.79%) and 26.5% (20.39-33.25%), respectively, for a total cost per patient of €6,619 (€5,902-€6,929), €6,394 (€5,881-€6,904), €6,855 (€5,800-€7,410) and €7,173 (€6,608-€7,763), respectively. Key model drivers were ER and antibiotic treatment duration, with hospital costs accounting for over 83% of the total expenditures. Given its clinical and safety profile, CFT is an acceptable choice for cSSTI empiric therapy providing comparable ER and costs to other relevant antibiotic options.